Pirtobrutinib (LOXO-305) Accelerated Approval

John introduces pirtobrutinib (brand name Jaypirca) for relapsed/refractory mantle cell lymphoma after BTKi, noting it is non-covalent.

Play episode from 14:08

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!